Congestive heart failure is one of the highest-cost diseases driving hospital readmissions and healthcare costs in the U.S. A highly effective treatment for preventing hospital readmissions of heart failure patients is intensive cardiac rehab. The intensive cardiac rehab benefits under Medicare and commercial payers pay physicians and hospitals surprisingly good reimbursement. Learn more: https://datarise.cokergroup.com/blog/2025/10/31/crush-readmissions-make-money-with-cardiac-rehab/

Premature birth interrupts the normal development of blood vessels in infants' eyes. If not diagnosed and treated in a timely manner, retinopathy of prematurity (ROP) can result in retinal detachment and blindness. Hospital neonatal intensive care units (NICUs) have a compelling need to contract with pediatric ophthalmologists to provide ROP screening and treatment services. Learn more: https://datarise.cokergroup.com/blog/2025/10/12/retinopathy-of-prematurity-fmv-of-pediatric-ophthalmology-services/

Alaska has fewer physician residents-in-training than any other U.S. state except Wyoming. Together with Alaska's remote location, nine hundred miles from Washington State, these factors create one of the most challenging markets for attracting and retaining physicians. Learn more: https://datarise.cokergroup.com/blog/2025/10/02/alaska-the-outlier-state-for-physician-services/

Medical geneticists and molecular pathologists play a major role in the growing fields of genomic testing and molecular diagnostics. Reimbursement for professional interpretation of these tests has fallen through the cracks of a complex system. Learn more: https://datarise.cokergroup.com/blog/2025/09/16/fair-market-value-for-interpretation-of-molecular-diagnostic-genomic-tests/

Cardinal, McKesson, and Cencora have been busy during the past two years. These three drug distributors have spent over $17 billion acquiring large specialty medical groups from private equity sellers. Close review of the target acquisitions reveals a compelling business strategy involving in-office drug infusions, injections, and dispensing. Learn more at: https://datarise.cokergroup.com/blog/2025/08/27/17-billion-in-doctor-deals-done-by-drug-distributors/

National physician enterprises set compensation rates in dozens or even hundreds of different markets. Clearly physicians in Alaska and San Francisco should not be compensated "the same" as physicians in rural Kansas and Arkansas. Today we'll talk about local market data for physician compensation. Learn more at: https://datarise.cokergroup.com/downloads/datarise-provider-compensation-data/

The 2025 commercial reimbursement rates for telemedicine are finally here. Today you'll get a glimpse of commercial reimbursement trends for telemedicine during 2025.

New commercial reimbursement rates are starting to appear in payor contracts for the 17 new telemedicine codes implemented during 2025. While Medicare still has a statutory requirement to pay telemedicine physician services at in-office rates, commercial insurance carriers are not required to follow Medicare's mandate. Learn more at: https://datarise.cokergroup.com/blog/2025/05/29/telemedicine-commercial-reimbursement-trends/

Nick Newsad shares customer feedback from DataRise PCD's first year and identifies three resulting enhancements to the subscription during 2025. The new Acuvance brand name is also discussed.

Scott Becker and Nick Newsad delve deeper into Scott's entrepreneurial journey as described in his new book The Entrepreneur's Edge. This episode covers Scott's views on marketing, content strategy at Becker's Healthcare, and memorable guest speakers. Scott describes personal interactions with George W. Bush, Hillary Clinton, Kareem Abdul-Jabbar, Bill Walton, and Nikki Haley. The Entrepreneur's Edge is available in Kindle, paperback, and hardcover: https://www.amazon.com/Entrepreneurs-Edge-Build-Manage-Business-ebook/dp/B0DBWYQPSJ

The most highly reimbursed hospital service during 2024 is the first of a whole new class of treatments. Chimeric Antigen Receptor (CAR) T-cell therapy tops the 2024 list, but an even more expensive hospital treatment just hit the market. Learn more at: https://health-contract.com/blog/2024/11/12/highest-2024-hospital-fees-signal-new-trend/